Repurposing drugs for glioblastoma: From bench to bedside. (1st August 2018)

• Record Type: Journal Article
• Authors: Basso, João; Miranda, Ana; Sousa, João; Pais, Alberto; Vitorino, Carla
• Is Part Of: Cancer letters. Volume 428(2018)
• Page Start: 173
• Page End: 183
• Publication Date: 2018-08-01
• Subjects: Drug repurposing -- Glioblastoma multiforme -- Pharmaceutical industry -- Clinical trial; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2018.04.039
• Languages: English
• ISSNs: 0304-3835

Abstract

Abstract: Glioblastoma multiforme is the most common, aggressive and lethal type of brain tumor. It is a stage IV cancer disease with a poor prognosis, as the current therapeutic options (surgery, radiotherapy and chemotherapy) are not able to eradicate tumor cells. The approach to treat glioblastoma has not suffered major changes over the last decade and temozolomide (TMZ) remains the mainstay for chemotherapy. However, resistance mechanisms to TMZ and other chemotherapeutic agents are becoming more frequent. The lack of effective options is a reality that may be counterbalanced by repositioning known and commonly used drugs for other diseases. This approach takes into consideration the available pharmacokinetic, pharmacodynamic, toxicity and safety data, and allows a much faster and less expensive drug and product development process. In this review, an extensive literature search is conducted aiming to list drugs with repurposing usage, based on their preferential damage in glioblastoma cells through various mechanisms. Some of these drugs have already entered clinical trials, exhibiting favorable outcomes, which sparks their potential application in glioblastoma treatment. Highlights: Repurposing saves money and time relative to traditional drug development process. Glioblastoma drug repurposing has been found in different therapeutic areas. Central nervous system drugs exhibit the marker anti-glioblastoma activity. Mechanisms of action in glioblastoma varies within repurposed therapeutic classes. Favourable clinical trials outcomes support the potential of repurposed drugs.